Overview

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH
Phase:
Phase 3
Details
Lead Sponsor:
Alexion Pharmaceuticals
Treatments:
Eculizumab